Otonomy Competitors and Similar CompaniesClear all
Otonomy's competitors and similar companies include Biogen.
 Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | |
Founding Date | Founding Date 2008 | Founding Date 1978 |
Type | Type Public | Type Public |
Tags | ||
Locations | Locations San Diego, US HQ | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 49 | Employees 7,605 |
Valuation ($) | Valuation ($) 5.3 m | Valuation ($) 26.7 b |
Financial | ||
Revenue (est.) | Revenue (est.) $125k (FY, 2021) | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods $370k (FY, 2021) | Cost of goods $2.4b (FY, 2025) |
Net income | Net income ($51.2m) (FY, 2021) | Net income $1.3b (FY, 2025) |
Operating ⚠ | ||
Phase I Trials Products | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products 4 (FY, 2024) |
Phase II Trials Products | Phase II Trials Products 2 (FY, 2016) | Phase II Trials Products 6 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products 11 (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
Biogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company